Navigation Links
Allergan to Present at The Leerink Partners 6th Annual Global Healthcare Conference
Date:2/9/2017

DUBLIN, Feb. 9, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) a leading global pharmaceutical company, today announced that David Nicholson, Allergan's Chief R&D Officer will deliver a presentation at the Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15th, 2016 at 1:30 p.m. ET in New York, New York.

The presentation will be webcast live and can be accessed on Allergan's Investor Relations web site at http://ir.allergan.com. The webcast can also be accessed through the following URL: http://wsw.com/webcast/leerink28/agn.

An archived version will be available approximately two hours after the live presentation ends and can be accessed at the same locations for 180 days.

About Allergan plcAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, the Company's R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs in development.

Our Company's success is powered by our more than 16,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS: Allergan: Investors:Lisa DeFrancesco (862) 261-7152Media:Mark Marmur (862) 261-7558

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-to-present-at-the-leerink-partners-6th-annual-global-healthcare-conference-300405374.html


'/>"/>
SOURCE Allergan plc
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg
2. Apollo Endosurgery Announces Acquisition of Obesity Intervention Division from Allergan, Inc.
3. Apollo Endosurgery Completes Acquisition of Allergan Inc.s Obesity Intervention Division
4. Increasing Use of Allergans Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
5. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
6. Valeant Pharmaceuticals Submits HSR Filing Relating To Proposed Acquisition Of Allergan
7. Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergans False and Misleading Statements
8. Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergans False And Misleading Statements
9. Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
10. Institutional Shareholder Services (ISS) Recommends Allergan Shareholders Call A Special Meeting Of Shareholders
11. Valeant Extends Offer To Acquire Allergan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/14/2019)... ... September 13, 2019 , ... ... Montreal provided a plethora of breakthrough research studies including several cancer related ... detect breast cancer, response prediction of cancer immunotherapies and whole body, real-time ...
(Date:9/14/2019)... , ... September 14, 2019 , ... ... continuing medical education (CME) courses, is announcing its attempt at a world record ... opportunity to prepare for the PANRE while earning 30 CME credits in 30 ...
(Date:9/11/2019)... ... September 12, 2019 , ... Understanding the Drug Supply ... Webinar, Thursday, Sept. 26, 2019, 1:30-3:00 p.m. EDT, https://www.fdanews.com/understanding-the-dscsa , Need ... the company clear on nuances of the guidelines regulating the drug supply chain? ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... 17, 2019 , ... What if a drug that sits ... patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) ... evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing ...
(Date:9/17/2019)... ... September 17, 2019 , ... Specialty Technical Publishers (STP) and ... Protocol Consortium (IAPC) EHS audit protocol for Japan . Leading companies around ... EHS regulatory obligations and rapidly collect, share, archive, and export audit findings in ...
(Date:9/17/2019)... ... September 17, 2019 , ... CORE Medical & Wellness, ... (Jenny) Gartshteyn to their team of expert physicians. Dr. Gartshteyn completed her Rheumatology ... Appointment of Assistant Professor in Medicine for the Division of Hospitalist Medicine. , ...
(Date:9/14/2019)... ... , ... GreenTheVoteOk , one of the most reliable online resource providers ... most relevant and important developments in the fast-changing world of legalized CBD. , ... across the world suffering from different difficult-to-treat ailments, people need to identify brands that ...
(Date:9/11/2019)... ... September 11, 2019 , ... Workplace ... have struggled to solve injury risks which lead to musculoskeletal disorders (MSDs). ... solution developed by the team at Soter Analytics helps avoid ergonomic ...
Breaking Medicine News(10 mins):